Augusta University
United States
Georgia CaRes
Augusta University has been home to Georgia’s NCI Community Oncology Research Program since 2014. In partnership with University Blood and Cancer Center in Athens, Phoebe Putney Medical Hospital in Albany, Augusta Oncology Associates in Augusta, and Dwight D. Eisenhower Army Medical Center in Augusta, the Georgia CaRes NCORP has over 1550 enrollments in NCI clinical trials (including cancer control, treatment, biospecimens, and special entries). The main goals of this application are to sustain and grow our NCORP Community Site, focusing on improving patient outcomes in cancer care throughout the State of Georgia and beyond. Our original program was aptly named Georgia CaRes (Georgia Cancer Research) and represents our shared commitment to cancer research including studies in cancer control, cancer prevention, and cancer care delivery, as well as clinical trials from NCI’s National Clinical Trials Network (NCTN). The renewal of Georgia CaRes will allow us to continue to serve large portions of the state with high concentrations of rural populations. We will accomplish this through the following Specific Aims: 1) Georgia CaRes will facilitate participation and enrollment of patients and healthcare providers into cancer control, prevention, and cancer cared delivery research (CCDR) studies developed by NCI’s Research Bases and in human research trials of the National Clinical Trials Network (NCTN); 2) Georgia CaRes will support and strengthen NCORP goals by improving the scope of our activities as an NCORP Community Site; 3) Georgia CaRes will increase collaboration across our NCORP Community network and with the Research Bases. Renewal of Georgia CaRes will have a significant and far-reaching impact on the health of cancer patients within the State of Georgia and beyond.
Publications
- Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Nov 1;39(31):3522-3524. Epub 2021 Sep 23. PMID: 34554848
- Kong FS, Hu C, Pryma DA, Duan F, Matuszak M, Xiao Y, Ten Haken R, Siegel MJ, Hanna L, Curran WJ, Dunphy M, Gelblum D, Piert M, Jolly S, Robinson CG, Quon A, Loo BW, Srinivas S, Videtic GM, Faria SL, Ferguson C, Dunlap NE, Kundapur V, Paulus R, Siegel BA, Bradley JD, Machtay M. Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Nov 20;42(33):3935-3946. Epub 2024 Oct 4. PMID: 39365957
- Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast cancer research and treatment. 2017 Sep;165(2):375-382. Epub 2017 Jun 16. PMID: 28623430
- Barton DL, Atherton PJ, Satele DV, Qin R, Dakhil S, Pipe T, Hobday T, Fee-Schroeder K, Loprinzi CL. A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020 Dec;28(12):6085-6094. Epub 2020 Apr 19. PMID: 32307658
- Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112
- Saba NF, Flamand Y, Lin DT, Chung CH, McDonald MW, Flampouri S, Khan SA, Snyderman CH, Hanna EY, El-Sayed IH, Solares CA, Le CH, Ghaly M, Hwang PH, Shin DM, Axelrod RS, Ikpeazu CV, Adkins DR, Duan F, Cohen M, Samuels MA, Swiecicki PL, Subramaniam RM, Chakravarthy AB, Burtness BA. Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025 Jun 13;31(12):2339-2346. PMID: 40227186
- Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 May 15;24(10):2285-2293. Epub 2018 Mar 2. PMID: 29500276
- Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15;130(10):1747-1757. Epub 2024 Jan 18. PMID: 38236702